GDP in Frontline Chemotherapy for Patients With PTCL-NOS
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of GDP (gemcitabine, dexamethasone, and
cisplatin) chemotherapy in patients with peripheral T-cell lymphoma-NOS as frontline
treatment.